Who are Adjuvant FL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LV5FU2, TS-1, ATRA plus 6-MP and MTX, Fluorouracil + folinic acid, Chemotherapy（pemetrexed/gemcitabine）, Folinic Acid + 5 FU.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adjuvant-fl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Adjuvant FL — Competitive Intelligence Brief

Adjuvant FL (Adjuvant FL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite chemotherapy combination. Area: Oncology.

phase 2 Antimetabolite chemotherapy combination Thymidylate synthase (via fluorouracil) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Adjuvant FL (Adjuvant FL) — Asan Medical Center. Adjuvant FL is a fluorouracil and leucovorin combination chemotherapy regimen designed to enhance immune response and reduce recurrence in cancer patients.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adjuvant FL TARGET	Adjuvant FL	Asan Medical Center	phase 2	Antimetabolite chemotherapy combination	Thymidylate synthase (via fluorouracil)
LV5FU2	LV5FU2	Centre Hospitalier Universitaire de Besancon	phase 3	Antimetabolite chemotherapy combination	Thymidylate synthase
TS-1	TS-1	National Health Research Institutes, Taiwan	phase 3	Antimetabolite chemotherapy combination	Thymidylate synthase
ATRA plus 6-MP and MTX	ATRA plus 6-MP and MTX	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	Retinoid plus antimetabolite chemotherapy combination	PML-RARA fusion protein (ATRA); DHFR and TPMT (MTX and 6-MP)
Fluorouracil + folinic acid	Fluorouracil + folinic acid	Odense University Hospital	phase 3	Antimetabolite chemotherapy combination	Thymidylate synthase
Chemotherapy（pemetrexed/gemcitabine）	Chemotherapy（pemetrexed/gemcitabine）	Shanghai Pulmonary Hospital, Shanghai, China	phase 3	Antimetabolite chemotherapy combination	Thymidylate synthase, dihydrofolate reductase (pemetrexed); ribonucleotide reductase, DNA polymerase (gemcitabine)
Folinic Acid + 5 FU	Folinic Acid + 5 FU	Pfizer	phase 3	Antimetabolite chemotherapy combination	Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite chemotherapy combination class)

Asan Medical Center · 1 drug in this class
Centre Hospitalier Universitaire de Besancon · 1 drug in this class
National Health Research Institutes, Taiwan · 1 drug in this class
Odense University Hospital · 1 drug in this class
Pfizer · 1 drug in this class
Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adjuvant FL — Competitive Intelligence Brief. https://druglandscape.com/ci/adjuvant-fl. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab